Studies clash on Russian vaccine's efficacy against omicron
The developer of Russia’s Sputnik V says its vaccine provides the best protection against the omicron variant of the coronavirus
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The developer of Russia’s Sputnik V said Friday that its vaccine provides the best protection against the omicron variant of the coronavirus, disputing a Western study which found Sputnik produced no antibodies against the new variant.
The Gamaleya Institute and the Russian Direct Investment Fund which bankrolled Sputnik V and its one-shot version called Sputnik Light, said in a statement that a preliminary laboratory study showed Sputnik V had “the best virus neutralization results against omicron in comparison with other vaccines”.
Russian President Vladimir Putin praised Sputnik V efficiency against omicron earlier Friday.
“Our Sputnik V is working well, and, perhaps, even more effective against the omicron than other vaccines used,” the president said during a congress of the Russian Union of Industrialists and Entrepreneurs.
Meanwhile, international researchers from the University of Washington and the Swiss drugmaker Humabs Biomed SA said in a study published Tuesday in pre-print and yet to be peer-reviewed that data they analyzed showed conflicting results.
The study, which used samples from health care workers in Buenos AiresArgentina who received Sputnik V, showed “no neutralizing activity against omicron.”
Russia has so far reported 25 cases of the omicron variant in the country, according to Deputy Prime Minister Tatiana Golikova.
The Gamaleya Institute disputed the foreign research findings, claiming they resulted from the use of "wrong serum samples".
"A recently published small study addresses Sputnik vaccine’s efficacy against omicron variant deliberately using serum samples that are not representative," the Russian center’s statement said.
___
Follow AP's coverage of the pandemic at https://apnews.com/hub/coronavirus-pandemic